Otsuka Gets Joint Development, Sales Rights For New Class Alzheimer Drug From Lundbeck
This article was originally published in PharmAsia News
Executive Summary
Otsuka acquired joint development and sales rights in Japan for Lu AE58054, a new class of Alzheimer drug, from Lundbeck.